Same-day restart of an HIV pill after stopping previous treatment
Part of Immune system & allergy, Infections clinical trials.
This study tests restarting a once-daily HIV pill (containing bictegravir, emtricitabine, and tenofovir alafenamide) on the same day it is prescribed, after stopping a different type of HIV medicine. It aims to see if this safe and convenient approach works well for people like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You stopped your previous NNRTI-based HIV medicine (a type of pill) more than 90 days ago.
- You do not have severe kidney or liver problems.
- You are not pregnant.
- You do not have a known resistance to bictegravir (the drug in this study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study tests whether switching to a different HIV pill (BIC/FTC/TAF) is safe and effective for people who had a viral failure while on the long-acting injectable CAB/RPV. It may offer a new option for those who need to change treatments.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This trial tests whether you can safely stop your HIV medication for a while if your immune system has specific markers that might help control the virus. The goal is to see if a treatment pause could be an option for people like you.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.